Celiprolol Treatment Linked to Improved Survival in vEDS Patients
The therapy celiprolol increased the survival rate and possibly lowered annual incidence of arterial events in patients with vascular Ehlers-Danlos syndrome (vEDS), according to results of a long-term study announced by Acer Therapeutics. The results were published in the Journal of the American College of Cardiology, in…